David Gillespie1, Christopher C Butler2, Janine Bates3, Kerenza Hood3, Hasse Melbye4, Rhiannon Phillips5, Helen Stanton3, Mohammed Fasihul Alam6, Jochen Wl Cals7, Ann Cochrane8, Nigel Kirby3, Carl Llor9, Rachel Lowe3, Gurudutt Naik10, Evgenia Riga11, Bernadette Sewell12, Emma Thomas-Jones3, Patrick White13, Nick A Francis14. 1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Centre for Trials Research, School of Medicine, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK. 2. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. 3. Centre for Trials Research, School of Medicine, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK. 4. General Practice Research Unit, Department of Community Medicine, UIT the Arctic University of Norway, Tromsø, Norway. 5. Cardiff School of Sport and Health Science, Cardiff Metropolitan University, Cardiff, UK. 6. Department of Public Health, College of Health Sciences, QU-Health, Qatar University, Doha, Qatar. 7. Department of Family Medicine, School for Public Health and Primary Care, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands. 8. York Trials Unit, Department of Health Sciences, University of York, York, UK. 9. Research Unit for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark; University Institute in Primary Care Research Jordi Gol, Via Roma Health Centre, Barcelona, Spain. 10. Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK. 11. Department of Psychiatry, Medical Sciences Division, University of Oxford, Oxford, UK. 12. Swansea Centre for Health Economics, Swansea University, Swansea, UK. 13. School of Population Health and Environmental Sciences, King's College London, London, UK. 14. Primary Care, Population Sciences and Medical Education, University of Southampton, Aldermoor Health Centre, Southampton, UK.
Abstract
BACKGROUND:C-reactive protein (CRP) point-of-care testing can reduce antibiotic use in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in primary care, without compromising patient care. Further safe reductions may be possible. AIM: To investigate the associations between presenting features and antibiotic prescribing in patients with AECOPD in primary care. DESIGN AND SETTING: Secondary analysis of a randomised controlled trial of participants presenting with AECOPD in primary care (the PACE trial). METHOD: Clinicians collected participants' demographic features, comorbid illnesses, clinical signs, and symptoms. Antibiotic prescribing decisions were made after participants were randomised to receive a point-of-care CRP measurement or usual care. Multivariable regression models were fitted to explore the association between patient and clinical features and antibiotic prescribing, and extended to further explore any interactions with CRP measurement category (CRP not measured, CRP <20 mg/l, or CRP ≥20 mg/l). RESULTS: A total of 649 participants from 86 general practices across England and Wales were included. Odds of antibiotic prescribing were higher in the presence of clinician-recorded crackles (adjusted odds ratio [AOR] = 5.22, 95% confidence interval [CI] = 3.24 to 8.41), wheeze (AOR = 1.64, 95% CI = 1.07 to 2.52), diminished vesicular breathing (AOR = 2.95, 95% CI = 1.70 to 5.10), or clinician-reported evidence of consolidation (AOR = 34.40, 95% CI = 2.84 to 417.27). Increased age was associated with lower odds of antibiotic prescribing (AOR per additional year increase = 0.98, 95% CI = 0.95 to 1.00), as was the presence of heart failure (AOR = 0.32, 95% CI = 0.12 to 0.85). CONCLUSION: Several demographic features and clinical signs and symptoms are associated with antibiotic prescribing in AECOPD. Diagnostic and prognostic value of these features may help identify further safe reductions.
RCT Entities:
BACKGROUND:C-reactive protein (CRP) point-of-care testing can reduce antibiotic use in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in primary care, without compromising patient care. Further safe reductions may be possible. AIM: To investigate the associations between presenting features and antibiotic prescribing in patients with AECOPD in primary care. DESIGN AND SETTING: Secondary analysis of a randomised controlled trial of participants presenting with AECOPD in primary care (the PACE trial). METHOD: Clinicians collected participants' demographic features, comorbid illnesses, clinical signs, and symptoms. Antibiotic prescribing decisions were made after participants were randomised to receive a point-of-care CRP measurement or usual care. Multivariable regression models were fitted to explore the association between patient and clinical features and antibiotic prescribing, and extended to further explore any interactions with CRP measurement category (CRP not measured, CRP <20 mg/l, or CRP ≥20 mg/l). RESULTS: A total of 649 participants from 86 general practices across England and Wales were included. Odds of antibiotic prescribing were higher in the presence of clinician-recorded crackles (adjusted odds ratio [AOR] = 5.22, 95% confidence interval [CI] = 3.24 to 8.41), wheeze (AOR = 1.64, 95% CI = 1.07 to 2.52), diminished vesicular breathing (AOR = 2.95, 95% CI = 1.70 to 5.10), or clinician-reported evidence of consolidation (AOR = 34.40, 95% CI = 2.84 to 417.27). Increased age was associated with lower odds of antibiotic prescribing (AOR per additional year increase = 0.98, 95% CI = 0.95 to 1.00), as was the presence of heart failure (AOR = 0.32, 95% CI = 0.12 to 0.85). CONCLUSION: Several demographic features and clinical signs and symptoms are associated with antibiotic prescribing in AECOPD. Diagnostic and prognostic value of these features may help identify further safe reductions.
Authors: Luis Nacul; Michael Soljak; Edgar Samarasundera; Nicholas S Hopkinson; Eliana Lacerda; Tejal Indulkar; Julian Flowers; Hannah Walford; Azeem Majeed Journal: J Public Health (Oxf) Date: 2010-06-03 Impact factor: 2.341
Authors: Rogier M Hopstaken; Christopher C Butler; Jean W M Muris; J André Knottnerus; Arnold D M Kester; Paula E L M Rinkens; Geert-Jan Dinant Journal: Fam Pract Date: 2005-12-02 Impact factor: 2.267
Authors: Kristin Alise Jakobsen; Hasse Melbye; Mark J Kelly; Christina Ceynowa; Sigvard Mölstad; Kerenza Hood; Christopher C Butler Journal: Scand J Prim Health Care Date: 2010-08-13 Impact factor: 2.581
Authors: G Rohde; A Wiethege; I Borg; M Kauth; T T Bauer; A Gillissen; A Bufe; G Schultze-Werninghaus Journal: Thorax Date: 2003-01 Impact factor: 9.139
Authors: Carl Llor; Ana Moragas; Silvia Hernández; Carolina Bayona; Marc Miravitlles Journal: Am J Respir Crit Care Med Date: 2012-08-23 Impact factor: 21.405
Authors: J C Aviles-Solis; C Jácome; A Davidsen; R Einarsen; S Vanbelle; H Pasterkamp; H Melbye Journal: BMC Pulm Med Date: 2019-09-11 Impact factor: 3.317
Authors: Janine Bates; Nick A Francis; Patrick White; David Gillespie; Emma Thomas-Jones; Rachel Breen; Nigel Kirby; Kerry Hood; Micaela Gal; Rhiannon Phillips; Gurudutt Naik; Jochen Cals; Carl Llor; Hasse Melbye; Mandy Wootton; Evgenia Riga; Ann Cochrane; Robin Howe; Deborah Fitzsimmons; Bernadette Sewell; Mohammed Fasihul Alam; Christopher C Butler Journal: Trials Date: 2017-09-29 Impact factor: 2.279
Authors: David Gillespie; Nick Francis; Haroon Ahmed; Kerenza Hood; Carl Llor; Patrick White; Emma Thomas-Jones; Helen Stanton; Bernadette Sewell; Rhiannon Phillips; Gurudutt Naik; Hasse Melbye; Rachel Lowe; Nigel Kirby; Ann Cochrane; Janine Bates; Mohammed Fasihul Alam; Christopher Butler Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-02-16